Almost everything the community talks about in the weight-loss space routes through one receptor family: GLP-1, GIP, glucagon, amylin, and the growing list of combinations stacked on top of them. Corbus Pharmaceuticals just put topline data on the table from something that works entirely outside that axis, and the early numbers are interesting enough that the non-incretin conversation is worth restarting.
CRB-913 is an orally delivered, peripherally restricted CB1 inverse agonist, a descendant of the rimonabant lineage that was pulled from the European market back in 2008 for psychiatric adverse events. Corbus reported positive topline results from its CANYON-1 phase 1b trial, with the data selected for a late-breaking presentation at ObesityWeek 2026 (14-17 November, Washington DC).
What the Research Says
- CANYON-1 was a 16-week double-blind, placebo-controlled, dose-ranging study in 254 obese, non-diabetic adults at 15 US sites, registered as NCT07310901. Participants were randomised 1:1:1:1 to CRB-913 20 mg, 40 mg or 60 mg orally once daily, or placebo.
- Least-squares mean weight change from baseline at week 12 was -2.8% at 20 mg, -3.3% at 40 mg and -5.0% at 60 mg, versus 0.0% for placebo, all P<0.0001.
- The company reports no evidence of a plateau at any dose by week 12, which is notable this early in a trial of this size.
- Psychiatric adverse events were reported as broadly in line with GLP-1 drugs, with no serious or severe psychiatric events recorded, which is the headline safety claim given the class history.
- Trial investigator Dr Harold Bays framed the clinical gap the drug is aiming at: a substantial share of patients cannot tolerate GLP-1s or get inadequate response, and over 60% discontinue within the first year.
Why the rimonabant ghost matters
The original CB1 inverse agonist story ended badly. Rimonabant (Acomplia) was approved in Europe in 2006 and withdrew it by 2008 after suicidality and depression signals, and the FDA never approved it at all. That failure cast a long shadow: the endocannabinoid system is one of the clearest levers on appetite and metabolic function in the body, and the field has largely avoided it for two decades because the first attempt hit the brain too hard.
CRB-913’s entire design premise is peripheral restriction. The molecule is meant to act on CB1 receptors outside the central nervous system, in adipose tissue, gut and liver, while staying out of the brain where the psychiatric risk lived. Whether that design actually delivers the class promise without the class liability is what phase 2 will start to answer, and one 16-week phase 1b with no serious psychiatric events is a signal, not a clearance. Rimonabant’s problems also surfaced at longer exposure and in a bigger population, so the honest read is cautious interest, not vindication.
Where it sits against the incretin numbers
Five percent placebo-adjusted weight loss at 12 weeks is modest next to what a good GLP-1 does in the same window, and nobody should pretend otherwise. The interesting part is the trajectory claim. If weight loss has genuinely not plateaued at week 12, the 16 and 24-week figures from the phase 2 could land in a range that starts to matter, particularly for an oral that does not require the titration burden of the injectables. Our oral GLP-1 pipeline coverage shows how high that bar has gotten for the small-molecule incretins.
The commercial logic is not “beat the GLP-1s” but “be the option for the people the GLP-1s fail.” That is the same population the Cleveland Clinic bariatric data is aimed at, and it is a very large group: the response distributions in the major incretin trials show a meaningful tail of low or non-responders.
Relevance for Australia
No TGA presence, no scheduling, no application, and realistically years from any filing that would reach here. The reason this matters to an Australian research-education audience is structural: the entire weight-management pipeline is incretin-concentrated, and any new mechanism reaching positive human data widens the map of what is biologically possible. If CB1 inverse agonism re-enters the pharmacopeia with a safer peripheral profile, that is a genuinely new research direction, and the community will want to understand the mechanism before the compounds show up on grey-market vendor lists, which they inevitably and prematurely will.
Our retatrutide and semaglutide pages carry the incretin benchmark datasets for comparison.
The Grey Highway Telegram group has a thread going on the ObesityWeek late-breakers, including the CRB-913 safety breakdown.
Sources
Source: Corbus Pharmaceuticals, “Corbus’ Oral CB1 Inverse Agonist CRB-913 Delivers 5% Weight Loss at 12 Weeks in Phase 1b CANYON-1 Trial”, topline data announcement, October 2026: https://trial.medpath.com/news/corbus-oral-cb1-inverse-agonist-crb-913-delivers-5-weight-loss-at-12-weeks-in-phase-1b-canyon-1-trial
Source: ClinicalTrials.gov, NCT07310901, “CRB-913 Obesity Efficacy, Safety and Pharmacokinetics (CANYON-1)”: https://clinicaltrials.gov/study/NCT07310901
Source: ObesityWeek 2026, The Obesity Society, 14-17 November 2026, Washington DC (late-breaking programme): https://obesity.org/obesityweek/
Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.